dr. cuellar on concerns with extrapolating data for biosimilars
Published 4 years ago • 154 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
1:16
dr. cuellar on the pharmacoeconomic benefits of biosimilars
-
0:42
dr. cristofanilli on the need for biosimilars in oncology
-
9:26
the future direction of biosimilars
-
0:45
dr. preeshagul on education for biosimilars in oncology
-
0:49
dr. robson discusses differences between biosimilars and biologics in oncology
-
1:04:35
unlocking the link between fiber, gut health, and cancer with dr. will bulsiewicz
-
12:54
oncotarget: onc201 kills breast cancer cells in vitro by targeting mitochondria
-
1:05:52
migara kavishka jayasinghe: surface-functionalized extracellular vesicles for targeted drug delivery
-
11:51
inverse balance in plasma levels of the endocannabinoids (...) - cecilia costiniuk
-
0:53
dr. schmid on evaluating biosimilars in oncology
-
0:52
dr. offin on potential implications of introducing biosimilars into oncology
-
8:03
navigating biosimilars: extrapolation, naming, substitution (blue line)
-
2:29
optimal prehospital crystalloid volume
-
0:36
unmet needs in extrapulmonary neuroendocrine carcinomas
-
2:28
cortical circuit research: the william zeiger lab
-
1:09
dr. kolberg provides a global perspective on biosimilar integration
-
1:46
the complex interplay between the immune microenvironment and tumor cells in multiple myeloma
-
0:55
the impact of mrd & genetics on outcomes to time-limited combinations in patients with cll
-
0:57
dr. somer on the expansion of biosimilars in oncology
-
1:41
dr. logan discusses acalabrutinib in cll
-
1:55
dr. kolberg on collecting real-world biosimilar trastuzumab data in breast cancer
-
2:43
resistance mechanisms of current treatments in cll